Elicio Therapeutics (ELTX)
Market Price (5/24/2026): $9.91 | Market Cap: $180.5 MilSector: Health Care | Industry: Biotechnology
Elicio Therapeutics (ELTX)
Market Price (5/24/2026): $9.91Market Cap: $180.5 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Oncology Treatments, Targeted Therapies, Show more. | Weak multi-year price returns2Y Excs Rtn is -42%, 3Y Excs Rtn is -58% Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 11.62 | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -37 Mil Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -26% Key risksELTX key risks include [1] a dependence on securing additional funding to maintain operations, Show more. |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Oncology Treatments, Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -42%, 3Y Excs Rtn is -58% |
| Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 11.62 |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -37 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -26% |
| Key risksELTX key risks include [1] a dependence on securing additional funding to maintain operations, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Anticipation of Positive Clinical Trial Data from ELI-002 7P. The stock experienced positive momentum due to the ongoing Phase 2 AMPLIFY-7P trial for ELI-002 7P in KRAS-driven pancreatic cancer, with primary disease-free survival (DFS) analysis expected mid-year 2026. Interim observations have noted "fewer disease progressions and deaths than projected" within the blinded study, contributing to a positive outlook.
2. Strong Analyst Endorsements and Elevated Price Targets. During the period, Elicio Therapeutics received multiple positive analyst ratings and increased price targets. Notably, Ladenburg Thalmann initiated coverage with a "Buy Now" rating and a $20 price target on April 15, 2026. HC Wainwright & Co. also raised its price target from $13 to $17 on March 13, 2026, maintaining a "Buy Now" rating. The consensus among analysts resulted in an average price target ranging from $15.75 to $18.00, suggesting significant upside potential.
Show more
Stock Movement Drivers
Fundamental Drivers
The 30.9% change in ELTX stock from 1/31/2026 to 5/23/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 1312026 | 5232026 | Change |
|---|---|---|---|
| Stock Price ($) | 7.60 | 9.95 | 30.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 17 | 18 | -8.3% |
| Cumulative Contribution | 0.0% |
Market Drivers
1/31/2026 to 5/23/2026| Return | Correlation | |
|---|---|---|
| ELTX | 30.9% | |
| Market (SPY) | 8.1% | 37.3% |
| Sector (XLV) | -2.7% | 21.1% |
Fundamental Drivers
The 7.1% change in ELTX stock from 10/31/2025 to 5/23/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 10312025 | 5232026 | Change |
|---|---|---|---|
| Stock Price ($) | 9.29 | 9.95 | 7.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 16 | 18 | -11.8% |
| Cumulative Contribution | 0.0% |
Market Drivers
10/31/2025 to 5/23/2026| Return | Correlation | |
|---|---|---|
| ELTX | 7.1% | |
| Market (SPY) | 9.9% | 33.7% |
| Sector (XLV) | 4.8% | 24.9% |
Fundamental Drivers
The 102.2% change in ELTX stock from 4/30/2025 to 5/23/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 4302025 | 5232026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.92 | 9.95 | 102.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 14 | 18 | -25.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
4/30/2025 to 5/23/2026| Return | Correlation | |
|---|---|---|
| ELTX | 102.2% | |
| Market (SPY) | 36.0% | 26.7% |
| Sector (XLV) | 8.6% | 17.6% |
Fundamental Drivers
The 31.0% change in ELTX stock from 4/30/2023 to 5/23/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 4302023 | 5232026 | Change |
|---|---|---|---|
| Stock Price ($) | 7.60 | 9.95 | 31.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 10 | 18 | -42.5% |
| Cumulative Contribution | 0.0% |
Market Drivers
4/30/2023 to 5/23/2026| Return | Correlation | |
|---|---|---|
| ELTX | 31.0% | |
| Market (SPY) | 86.3% | 10.1% |
| Sector (XLV) | 18.0% | 11.5% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ELTX Return | -83% | -72% | 3% | -39% | 56% | 24% | -94% |
| Peers Return | 18% | -11% | -21% | -28% | -14% | 24% | -36% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 9% | 98% |
Monthly Win Rates [3] | |||||||
| ELTX Win Rate | 36% | 25% | 42% | 50% | 58% | 20% | |
| Peers Win Rate | 48% | 52% | 35% | 43% | 50% | 52% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| ELTX Max Drawdown | - | -73% | -67% | -67% | -51% | -34% | |
| Peers Max Drawdown | -44% | -43% | -51% | -55% | -50% | -25% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: MRNA, MRK, BMY, IOVA, AGEN.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/22/2026 (YTD)
How Low Can It Go
| Event | ELTX | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -41.7% | -18.8% |
| % Gain to Breakeven | 71.4% | 23.1% |
| Time to Breakeven | 81 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -44.3% | -9.5% |
| % Gain to Breakeven | 79.4% | 10.5% |
| Time to Breakeven | 142 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -26.2% | -6.7% |
| % Gain to Breakeven | 35.4% | 7.1% |
| Time to Breakeven | 21 days | 31 days |
In The Past
Elicio Therapeutics's stock fell -41.7% during the 2025 US Tariff Shock. Such a loss loss requires a 71.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | ELTX | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -41.7% | -18.8% |
| % Gain to Breakeven | 71.4% | 23.1% |
| Time to Breakeven | 81 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -44.3% | -9.5% |
| % Gain to Breakeven | 79.4% | 10.5% |
| Time to Breakeven | 142 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -26.2% | -6.7% |
| % Gain to Breakeven | 35.4% | 7.1% |
| Time to Breakeven | 21 days | 31 days |
In The Past
Elicio Therapeutics's stock fell -41.7% during the 2025 US Tariff Shock. Such a loss loss requires a 71.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Elicio Therapeutics (ELTX)
AI Analysis | Feedback
Here are 1-3 brief analogies for Elicio Therapeutics:
- An early-stage Moderna, but focusing its novel vaccine technology on cancer immunotherapies rather than infectious diseases.
- A tiny Bristol Myers Squibb, specializing in unique therapeutic vaccines for specific cancers like KRAS-driven tumors.
AI Analysis | Feedback
```html- ELI-002: An AMP therapeutic vaccine developed for the treatment of KRAS-driven cancers.
- ELI-004: An AMP-modified CpG adjuvant designed to treat or prevent a range of diseases.
- ELI-003: A product candidate targeting cancers that involve an ALK mutation.
- ELI-011: A therapeutic candidate developed for hematological cancers.
- ELI-005: A product specifically for the prevention of COVID-19.
- ELI-002 7P (AMPLIFY-7P): A vaccine designed for mutated solid tumors.
AI Analysis | Feedback
Elicio Therapeutics (ELTX) is a clinical-stage biotechnology company focused on the research and development of novel immunotherapies and conducting clinical trials for its product candidates. As such, the company does not currently have major customers for commercially available products in the traditional sense. Its activities are centered on advancing its pipeline through clinical development.
AI Analysis | Feedback
nullAI Analysis | Feedback
Robert Connelly, Chief Executive Officer and PresidentRobert Connelly has served as CEO and Director of Elicio Therapeutics since June 2023, and previously as CEO and a director of Former Elicio from October 2018 until the merger with Angion on June 1, 2023. He brings 35 years of life sciences leadership, including over 24 years as CEO. His prior CEO roles include Axcella (2013–2018), Pulmatrix (2007–2012), and he was the founding CEO of Domantis (2000–2007), which was acquired by GSK plc in 2007 for $454 million. He also served as a Venture Partner at Flagship Pioneering from 2013-2018, focusing on company creation and portfolio management across biotech ventures. Earlier in his career, he held various roles at Abbott Laboratories and BioVeris, which was later acquired by Roche for $1.6 billion.
Preetam Shah, PhD, MBA, Chief Strategy and Financial Officer
Preetam Shah was appointed as Elicio Therapeutics' Chief Strategy and Financial Officer on March 24, 2025. He brings extensive leadership experience from his previous roles as CFO and Chief Business Officer (CBO) at several publicly traded biotechnology companies, including Cidara Therapeutics and Brainstorm Cell Therapeutics. Dr. Shah also has a background in investment banking, having held positions at Barclays Capital and Canaccord Genuity.
Christopher Haqq, MD, PhD, Executive Vice President, Head of Research and Development and Chief Medical Officer
Dr. Christopher Haqq joined Elicio Therapeutics in October 2019. He possesses over 20 years of drug development leadership experience across both large and small biotechnology companies, spanning cell therapy, small molecule, and biologics modalities. Prior to Elicio, he was the first employee and Chief Medical Officer, and later Chief Scientific Officer, of Atara Biotherapeutics. His career also includes being the lead clinician for a pivotal prostate cancer study at Cougar Biotechnology and Janssen, which led to the market approval of Zytiga® (abiraterone acetate). He also led early development studies at Amgen. Dr. Haqq initially practiced as a medical oncologist and directed a translational science laboratory as an Assistant Professor at the University of California, San Francisco.
Peter DeMuth, PhD, Chief Scientific Officer
Peter DeMuth serves as the Chief Scientific Officer of Elicio Therapeutics. He is a co-inventor of the Amphiphile (AMP) platform technology, which is central to Elicio's therapeutic approach. His research and expertise are focused on drug delivery, immunology, and immuno-oncology.
Marc Wolfgang, MS, Chief Technology Officer
Marc Wolfgang was appointed Chief Technology Officer of Elicio Therapeutics in November 2025. He brings more than 30 years of biopharmaceutical leadership experience, covering manufacturing, development, quality, and supply chain operations. Before joining Elicio, he was the Senior Vice President of Technical Development and Operations at Sail Biomedicines, and previously served as Vice President of U.S. Manufacturing at BioNTech.
AI Analysis | Feedback
The key risks to Elicio Therapeutics (ELTX) are primarily centered around its financial viability as a clinical-stage biotechnology company and the inherent challenges of drug development.
-
Funding and Going Concern Risk: Elicio Therapeutics is a clinical-stage company with no revenue, and it consistently reports negative free cash flow and persistent unprofitability. The company requires substantial additional capital to finance its operations. Its current cash and cash equivalents are projected to support operations only into Q3 2026, beyond the anticipated readout of its Phase 2 trial. The failure to secure necessary capital on acceptable terms, or at all, could force the company to delay, limit, reduce, or terminate its research and development programs and commercialization efforts, or even cease operations.
-
Clinical Trial Success and Product Concentration Risk: Elicio's valuation and future prospects are heavily dependent on the successful development and commercialization of its lead product candidate, ELI-002, an AMP therapeutic vaccine for KRAS-driven cancers. As a clinical-stage biotechnology company, its value is tied to the potential of its scientific platform and lead drug. A failure in the ongoing Phase 2 AMPLIFY-7P trial for ELI-002, or any other significant clinical setback, would be catastrophic for the company due to its concentrated pipeline and lack of diversification compared to competitors with multiple drug candidates. Biotech clinical trials inherently carry a high risk of failure.
-
Competition: Elicio Therapeutics operates in the highly competitive immuno-oncology market. It faces competition from numerous biotechnology and pharmaceutical companies, some of which have more advanced clinical programs, greater financial resources, and more established infrastructure. The competitive landscape includes companies also developing personalized cancer vaccines or immunotherapies for cancer, which could impact Elicio's potential market share and commercial success if its products reach the market.
AI Analysis | Feedback
nullAI Analysis | Feedback
Elicio Therapeutics (symbol: ELTX) has several main product candidates addressing various cancer types and infectious diseases. The addressable markets for these products are as follows:
- ELI-002 (AMP therapeutic vaccine for KRAS-driven cancers) and ELI-002 7P (vaccine for mutated solid tumors): The global KRAS inhibitors market was valued at over US$300 million in 2023 and is projected to surpass USD 600 million by 2030. It is anticipated to reach approximately USD 7,847 million by 2034 across the seven major markets (7MM), which include the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan, growing at a Compound Annual Growth Rate (CAGR) of 35% during the 2024–2034 forecast period. The United States is expected to be the dominant contributor, accounting for nearly 70% of the total KRAS inhibitors market share in 2024. In 2024, the total number of KRAS-mutated cases in the 7MM comprised more than 509,700 cases.
- ELI-003 (for cancers involving an ALK mutation): The global ALK-positive lung cancer treatment market is estimated to be USD 4.7 billion in 2025 and is expected to reach USD 9.8 billion by 2032, exhibiting a CAGR of 11.2% from 2025 to 2032. Another estimate places the global Cancer ALK Inhibitor Market at USD 1.5 billion in 2020, projected to reach USD 10.6 billion by 2030, with a CAGR of 22.0%. The ALK Non-Small Cell Lung Cancer (NSCLC) Market Size in the 7MM was approximately USD 2 billion in 2024 and is projected to increase through 2034. In the US, the ALK NSCLC market was over USD 1.2 billion in 2024. North America holds the largest revenue share in the ALK-positive lung cancer treatment market.
- ELI-011 (for hematological cancers): The global hematologic malignancies market was valued at approximately USD 75.76 billion in 2024 and is anticipated to reach around USD 164.65 billion by 2034, exhibiting a CAGR of roughly 8.10% during the forecast period of 2025-2034. Other reports estimate the global market size at USD 72.87 billion in 2024, expected to reach USD 147.38 billion by 2033 (CAGR 8.14%), or USD 81.74 billion in 2024, expected to reach USD 191.11 billion by 2032 (CAGR 11.20%). North America dominated the hematologic malignancies industry, accounting for a 41% share in 2024. In the United States, an estimated 187,740 individuals are projected to be diagnosed with leukemia, lymphoma, or myeloma in 2024.
- ELI-005 (product for the prevention of COVID-19): The global COVID-19 therapeutics market size was estimated at USD 32542.5 million in 2025 and is expected to decline at a CAGR of -15.20% from 2025 to 2033. The COVID-19 vaccines & drugs market is expected to decline from USD 2,273 million in 2022 to USD 1,401 million by 2025. North America held the major market share, over 40%, of the global COVID-19 therapeutics market in 2025.
AI Analysis | Feedback
Elicio Therapeutics (ELTX), a clinical-stage biotechnology company, is primarily focused on the development of novel immunotherapies for cancer. While analysts currently project no direct product revenue through 2027, future revenue growth over the next 2-3 years is expected to be driven by key clinical milestones and strategic collaborations rather than commercial product sales. Here are 3-5 expected drivers of future revenue growth for Elicio Therapeutics:-
Successful Clinical Development and Milestones for ELI-002 (AMPLIFY-7P): Elicio's lead product candidate, ELI-002 7P, an AMP therapeutic vaccine for KRAS-driven cancers, is a primary driver. The event-driven primary disease-free survival (DFS) analysis for the Phase 2 AMPLIFY-7P trial in resected mKRAS pancreatic ductal adenocarcinoma (PDAC) is anticipated in the first half of 2026. Positive results from this Phase 2 study could support rapid advancement into a Phase 3 trial. The company has already received supportive feedback from the FDA regarding the potential ELI-002 Phase 3 study design. Such significant clinical progress, while not immediately translating to product sales, could trigger milestone payments from existing or future partnerships and enhance the company's valuation, enabling future funding for commercialization efforts beyond this timeframe.
-
Formation of New Strategic Partnerships and Licensing Agreements: Elicio Therapeutics has a historical precedent of generating substantial revenue from "milestone payments or partnership upfronts." Analysts identify partnerships as key catalysts for revenue in the 2026-2027 period. As ELI-002 and other pipeline candidates advance through clinical development and demonstrate positive data, the company's proprietary AMP platform and its therapeutic applications become more attractive for collaborations, which could result in upfront payments and subsequent milestone payments.
-
Advancement and Data Readouts from Other Pipeline Candidates: Beyond ELI-002, the company's pipeline includes ELI-004, an AMP-modified CpG adjuvant for pan-solid tumors, with data anticipated in 2026-2027, which is also considered a key catalyst. Progress in these additional programs, such as positive clinical data for ELI-004, could broaden the appeal of Elicio's AMP platform and lead to new licensing opportunities or collaborations across different disease areas, contributing to future revenue streams.
AI Analysis | Feedback
Capital Allocation Decisions for Elicio Therapeutics (ELTX)
Share Issuance
- Elicio Therapeutics launched a new at-the-market (ATM) stock sales program in March 2026, authorizing the sale of up to $100.0 million of common stock from time to time.
- In February 2026, the company filed a shelf registration statement to offer up to $400.0 million of various securities, including common stock, preferred stock, debt securities, warrants, and units.
- The company executed several financing activities, including an approximately $11.5 million underwritten public offering of common stock and warrants in June 2024, a $20.0 million private placement of a convertible note in August 2024, and a $10.0 million registered direct offering in January 2025.
Inbound Investments
- GKCC, LLC, an entity controlled by a member of Elicio's Board of Directors, has been a recurring investor, providing $7.0 million in private placement financing in December 2023, $6.0 million in pre-funded warrant financing in March 2024, and a $20.0 million convertible note in August 2024.
- In June 2025, Elicio secured $10.0 million in financing through a senior secured promissory note from existing investor GKCC, LLC, also issuing warrants to purchase common stock.
- The company completed a $10.0 million registered direct offering to institutional investors in January 2025.
Capital Expenditures
- Elicio Therapeutics reported minimal capital expenditures, with $0 invested in Q3 2025.
- Research and development expenses, which reflect capital allocated to product development, were $7.0 million for the second quarter of 2025, a decrease from $8.2 million in the second quarter of 2024 due to less clinical trial manufacturing.
- The company anticipates an increase in future capital expenditures, driven primarily by continued development of product candidates, efforts to obtain regulatory approvals, and other costs associated with operating as a public company.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Elicio Therapeutics Earnings Notes | 12/16/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to ELTX.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 28.41 |
| Mkt Cap | 10.1 |
| Rev LTM | 1,245 |
| Op Inc LTM | -15 |
| FCF LTM | -63 |
| FCF 3Y Avg | -93 |
| CFO LTM | -63 |
| CFO 3Y Avg | -91 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 2.9% |
| Rev Chg 3Y Avg | 3.1% |
| Rev Chg Q | 40.2% |
| QoQ Delta Rev Chg LTM | 8.4% |
| Op Inc Chg LTM | 14.2% |
| Op Inc Chg 3Y Avg | 12.7% |
| Op Mgn LTM | 6.3% |
| Op Mgn 3Y Avg | -61.6% |
| QoQ Delta Op Mgn LTM | 5.1% |
| CFO/Rev LTM | -66.5% |
| CFO/Rev 3Y Avg | -73.5% |
| FCF/Rev LTM | -70.7% |
| FCF/Rev 3Y Avg | -91.2% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 10.1 |
| P/S | 4.6 |
| P/Op Inc | 2.1 |
| P/EBIT | -1.8 |
| P/E | -1.3 |
| P/CFO | -3.0 |
| Total Yield | -5.8% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -19.5% |
| D/E | 0.1 |
| Net D/E | 0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -5.3% |
| 3M Rtn | 1.2% |
| 6M Rtn | 29.3% |
| 12M Rtn | 69.7% |
| 3Y Rtn | -22.4% |
| 1M Excs Rtn | -10.4% |
| 3M Excs Rtn | -8.8% |
| 6M Excs Rtn | 19.3% |
| 12M Excs Rtn | 45.4% |
| 3Y Excs Rtn | -101.0% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Development of immunotherapies for patients with limited treatment options and poor outcomes | 0 | |||
| Total | 0 |
| $ Mil | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Development of immunotherapies for patients with limited treatment options and poor outcomes | 28 | 27 | 23 | 15 |
| Total | 28 | 27 | 23 | 15 |
Price Behavior
| Market Price | $9.95 | |
| Market Cap ($ Bil) | 0.2 | |
| First Trading Date | 02/05/2021 | |
| Distance from 52W High | -28.1% | |
| 50 Days | 200 Days | |
| DMA Price | $10.95 | $9.91 |
| DMA Trend | up | up |
| Distance from DMA | -9.2% | 0.4% |
| 3M | 1YR | |
| Volatility | 93.4% | 76.4% |
| Downside Capture | 347.23 | 177.46 |
| Upside Capture | 295.17 | 189.48 |
| Correlation (SPY) | 34.3% | 25.7% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.66 | 2.27 | 2.39 | 1.93 | 1.59 | 0.62 |
| Up Beta | 2.01 | 1.47 | 1.50 | 2.13 | 2.03 | 0.80 |
| Down Beta | -7.70 | 2.44 | 1.29 | 1.35 | 1.63 | 0.13 |
| Up Capture | 194% | 204% | 494% | 284% | 248% | 64% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 10 | 18 | 31 | 57 | 118 | 362 |
| Down Capture | 943% | 295% | 216% | 164% | 103% | 94% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 12 | 25 | 33 | 68 | 129 | 371 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ELTX | |
|---|---|---|---|---|
| ELTX | 71.8% | 76.6% | 1.03 | - |
| Sector ETF (XLV) | 16.0% | 14.5% | 0.80 | 18.7% |
| Equity (SPY) | 29.5% | 12.0% | 1.86 | 26.5% |
| Gold (GLD) | 35.5% | 26.8% | 1.11 | 13.5% |
| Commodities (DBC) | 42.9% | 18.7% | 1.77 | -6.4% |
| Real Estate (VNQ) | 15.2% | 13.1% | 0.82 | 19.5% |
| Bitcoin (BTCUSD) | -31.3% | 41.8% | -0.78 | 14.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ELTX | |
|---|---|---|---|---|
| ELTX | -46.5% | 97.6% | -0.16 | - |
| Sector ETF (XLV) | 5.7% | 14.7% | 0.21 | 14.5% |
| Equity (SPY) | 14.0% | 17.0% | 0.64 | 17.0% |
| Gold (GLD) | 18.8% | 18.0% | 0.85 | 3.4% |
| Commodities (DBC) | 10.4% | 19.4% | 0.42 | 3.5% |
| Real Estate (VNQ) | 3.8% | 18.8% | 0.10 | 14.7% |
| Bitcoin (BTCUSD) | 11.6% | 55.3% | 0.41 | 12.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ELTX | |
|---|---|---|---|---|
| ELTX | -28.4% | 97.8% | -0.16 | - |
| Sector ETF (XLV) | 9.9% | 16.5% | 0.49 | 14.6% |
| Equity (SPY) | 15.7% | 17.9% | 0.75 | 17.3% |
| Gold (GLD) | 13.0% | 16.0% | 0.67 | 4.5% |
| Commodities (DBC) | 7.8% | 17.9% | 0.35 | 3.9% |
| Real Estate (VNQ) | 5.5% | 20.7% | 0.23 | 14.6% |
| Bitcoin (BTCUSD) | 66.7% | 66.9% | 1.06 | 13.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/11/2026 | -9.1% | -17.6% | |
| 8/11/2023 | 0.0% | -0.1% | -9.1% |
| 8/15/2022 | -1.0% | -2.9% | 13.5% |
| 3/30/2022 | 3.9% | 7.4% | -38.7% |
| 11/12/2021 | -0.4% | -7.2% | -43.5% |
| 8/12/2021 | 2.2% | -11.8% | 0.2% |
| 3/30/2021 | 0.4% | -11.0% | -21.3% |
| SUMMARY STATS | |||
| # Positive | 4 | 1 | 2 |
| # Negative | 3 | 6 | 4 |
| Median Positive | 1.3% | 7.4% | 6.8% |
| Median Negative | -1.0% | -9.1% | -30.0% |
| Max Positive | 3.9% | 7.4% | 13.5% |
| Max Negative | -9.1% | -17.6% | -43.5% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/11/2026 | 10-Q |
| 12/31/2025 | 03/12/2026 | 10-K |
| 09/30/2025 | 11/13/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/13/2025 | 10-Q |
| 12/31/2024 | 03/31/2025 | 10-K |
| 09/30/2024 | 11/13/2024 | 10-Q |
| 06/30/2024 | 08/13/2024 | 10-Q |
| 03/31/2024 | 05/15/2024 | 10-Q |
| 12/31/2023 | 03/29/2024 | 10-K |
| 09/30/2023 | 11/13/2023 | 10-Q |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 12/31/2022 | 04/27/2023 | S-4/A |
| 03/31/2021 | 07/13/2021 | S-1/A |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.